|Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling|
AA Alizadeh, MB Eisen, RE Davis, C Ma, IS Lossos, A Rosenwald, ...
Nature 403 (6769), 503-511, 2000
|Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study|
P Fenaux, GJ Mufti, E Hellstrom-Lindberg, V Santini, C Finelli, ...
The lancet oncology 10 (3), 223-232, 2009
|Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia|
JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, KA Blum, B Grant, ...
New England Journal of Medicine 369 (1), 32-42, 2013
|Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid …|
JC Byrd, K Mrózek, RK Dodge, AJ Carroll, CG Edwards, DC Arthur, ...
Blood, The Journal of the American Society of Hematology 100 (13), 4325-4336, 2002
|Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia|
JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ...
New England Journal of Medicine 371 (3), 213-223, 2014
|Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia|
A Rosenwald, AA Alizadeh, G Widhopf, R Simon, RE Davis, X Yu, L Yang, ...
Journal of Experimental Medicine 194 (11), 1639-1648, 2001
|Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study|
MJ Keating, I Flinn, V Jain, JL Binet, P Hillmen, J Byrd, M Albitar, ...
Blood 99 (10), 3554-3561, 2002
|ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia|
LZ Rassenti, L Huynh, TL Toy, L Chen, MJ Keating, JG Gribben, ...
New England Journal of Medicine 351 (9), 893-901, 2004
|Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib|
JA Woyach, RR Furman, TM Liu, HG Ozer, M Zapatka, AS Ruppert, L Xue, ...
New England Journal of Medicine 370 (24), 2286-2294, 2014
|Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype|
CD Bloomfield, D Lawrence, JC Byrd, A Carroll, MJ Pettenati, ...
Cancer research 58 (18), 4173-4179, 1998
|MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly …|
R Garzon, S Liu, M Fabbri, Z Liu, CEA Heaphy, E Callegari, S Schwind, ...
Blood, The Journal of the American Society of Hematology 113 (25), 6411-6418, 2009
|Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765|
SEM Herman, AL Gordon, E Hertlein, A Ramanunni, X Zhang, ...
Blood 117 (23), 6287-6296, 2011
|CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability|
BJ Lannutti, SA Meadows, SEM Herman, A Kashishian, B Steiner, ...
Blood, The Journal of the American Society of Hematology 117 (2), 591-594, 2011
|Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia …|
JC Byrd, BL Peterson, VA Morrison, K Park, R Jacobson, E Hoke, ...
Blood, The Journal of the American Society of Hematology 101 (1), 6-14, 2003
|Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review.|
JC Byrd, WJ Edenfield, DJ Shields, NA Dawson
Journal of Clinical Oncology 13 (7), 1800-1816, 1995
|The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody|
DM Benson, CE Bakan, A Mishra, CC Hofmeister, Y Efebera, B Becknell, ...
Blood 116 (13), 2286-2294, 2010
|Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib|
JC Byrd, RR Furman, SE Coutre, JA Burger, KA Blum, M Coleman, ...
Blood 125 (16), 2497-2506, 2015
|Adult Burkitt leukemia and lymphoma|
KA Blum, G Lozanski, JC Byrd
Blood 104 (10), 3009-3020, 2004
|Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity|
JC Byrd, T Murphy, RS Howard, MS Lucas, A Goodrich, K Park, ...
Journal of Clinical Oncology 19 (8), 2153-2164, 2001
|Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia|
JC Byrd, B Harrington, S O’Brien, JA Jones, A Schuh, S Devereux, ...
New England Journal of Medicine 374 (4), 323-332, 2016